SRP4594
IFN-alpha 2a human
recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
Synonym(s):
B cell interferon, IFN-α 2A, IFNA2, Interferon α-2a, Leukocyte interferon, Type I interferon
biological source
human
recombinant
expressed in E. coli
Assay
≥95% (HPLC)
≥95% (SDS-PAGE)
form
lyophilized
potency
1x10^8 units/mg
mol wt
~19.4 kDa
packaging
pkg of 100 μg
storage condition
avoid repeated freeze/thaw cycles
impurities
endotoxin, tested
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... IFNA2(3440)
General description
The gene IFN-α2a (interferon α 2a) is mapped to human chromosome 9. The encoded protein is a type 1 interferon and a glycoprotein. It belongs to the class of cytokines. Recombinant human IFN-α 2a is a single, non-glycosylated, polypeptide chain with a molecular mass 19.4kDa containing 166 amino acid residues. Interferon-α-2a, a recombinant interferon-a, is expressed in Escherichia coli. It is eliminated majorly via renal catabolism. However, hepatic and biliary elimination comprise the minor pathways.
Application
IFN-α2a (interferon α 2a)-human has been used to study heterosexual transmission of subtype C HIV (human immunodeficiency virus)-1.
IFN-alpha 2a human has been used:
- as standard protein in reverse-phase high-performance liquid chromatography (RP-HPLC) and reducing and non-reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for characterizing recombinant consensus interferon (rh cIFN)
- as a supplement in Roswell Park Memorial Institute (RPMI) 1640 medium for studying interferon resistance in peripheral blood mononuclear cells (PBMC)
- to treat hepatocytes to test its effect on signal transducer and activator of transcription 1 (STAT1) mRNA levels and cytochrome P450 family 1 subfamily A member 2 (CYP1A2) expression
- to stimulate human monocyte derived macrophages (MDMs)
Biochem/physiol Actions
IFN-α2a (interferon α 2a) is a lymphoid factor that possesses potent anti-viral activity. It mainly interacts with cell surface-specific receptors. This interaction is responsible for anti-pathogenic response in cells. IFN-α2a also exhibits anti-tumor activities. Humans with brain tumor were shown to have mutations in this gene. Interferon-α-2a (IFN-a 2A) favors 2′5′-oligoadenylate synthetase and double-stranded RNA-dependent protein kinase induction to target viral mRNA and protein synthesis. IFN-α 2A exhibits immunomodulatory effects, inducing cytokines and other interferon production. It also increases natural killer and cytotoxic T cell activity, as well as histocompatibility complex antigen expression. It may be beneficial for treating hepatic cirrhosis, chronic hepatitis C and hepatitis D.
Physical form
Lyophilized without any additives.
Preparation Note
Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.
Reconstitute in water to a concentration of 0.1-1 mg/mL. This solution can then be diluted into other aqueous buffers.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
C M Perry et al.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 10(1), 65-89 (2007-11-21)
Interferon-alpha-2a, a single interferon-alpha subtype manufactured by use of recombinant DNA technology, has immmunomodulatory, antiviral and antiproliferative properties. It is a beneficial treatment for about 30% of patients with well-compensated chronic hepatitis C. Biochemical responses [defined as normalisation of serum
Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-a Resistance.
Deymier MJ
PLoS Pathogens, 11, e1005154-e1005154 (2015)
Nadeem Ahmed et al.
Biotechnology and applied biochemistry, 62(5), 699-708 (2014-11-18)
Recombinant human consensus interferon (rh-cIFN) is an artificially engineered interferon (IFN) developed by recombining and reordering the protein sequences that exist in standard IFN. This recombination resulted into a drug that has the potential to work better than natural, standard
Maciej Czerwiński et al.
Pharmacology research & perspectives, 7(6), e00551-e00551 (2019-12-21)
Some immunomodulatory agents stimulate the release of cytokines capable of suppressing P450 enzymes and potentially affecting pharmacokinetics of coadministered medications. Cytokines released in response to an immunomodulator in the blood ex vivo can be used to screen for the potential
Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions.
Shahid S
Cancer Gene Therapy, 22, 246-261 (2015)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service